• Clinical Evidence

Can Severe Hypoglycemia be Eliminated? Introducing Estimated Residual Extracellular Insulin (EREI)

Setting: Cohort of 84 community hospitals.

Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results

  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.

Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.
Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results
  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.
Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.

References

Authors

W. Patrick Burgess, PhD, MD; Laura Santana, RN; Laurel Fuqua, RN, MSN.

Source

Presented at Annual Diabetes Technology Meeting. Published in Journal of Diabetes Science and Technology, Volume 1, Issue 2, p373.

Year

2019

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective analysis compares incidence of hypoglycemia with and without use of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature.

Setting

Cohort of 84 community hospitals.

Results
  • Incidence of hypoglycemia <40 mg/dL was 63% lower when the EndoTool EREI adjustment feature was enabled.
  • Specifically, hypoglycemia occurred at a rate of one for every 351 patient days of intravenous insulin therapy with the EREI adjustment feature versus one for every 129 patient days without the EREI adjustment feature.
Conclusions

Use of the specialized EndoTool EREI adjustment feature significantly reduces incidence of hypoglycemia without significantly impacting glycemic control.

References

Authors

W. Patrick Burgess, PhD, MD; Laura Santana, RN; Laurel Fuqua, RN, MSN.

Source

Presented at Annual Diabetes Technology Meeting. Published in Journal of Diabetes Science and Technology, Volume 1, Issue 2, p373.

Year

2019

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

Near Elimination of Severe Hypoglycemia with EndoTool IV Across a 19-Hospital Health System

To evaluate the impact of EndoTool IV insulin dosing software on reducing severe hypoglycemia (SH) (blood glucose < 40 mg/dL) across 19-hospitals at a prominent health system, including outcomes in patients with renal insufficiency.
Image
  • Clinical Evidence

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

Temple Health Achieves Zero Severe Hypoglycemia in Renally Impaired Patients with EndoTool SubQ

To evaluate the safety and efficacy of the EndoTool SubQ (ETSQ) insulin dosing application for subcutaneous (SQ) insulin administration in hospitalized patients, and to compare clinical outcomes against those treated using a standard insulin order set. The analysis also examined performance in high-risk patients with advanced renal impairment.
Image
  • Clinical Evidence

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Improving Inpatient Glycemic Safety at Temple Health with EndoTool SubQ

Temple Health, a 3-hospital academic system was experiencing high rates of hypoglycemia due to reliance on sliding scale insulin (SSI). To improve safety and align with ADA guidelines, the hospital implemented EndoTool SubQ, a patient-specific insulin dosing software the supports four dosing protocols, including basal-bolus-correction (BBC).
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Name*
By submitting this form, you consent to the processing of your personal information, including sensitive personal information you provide, in accordance with the Monarch Medical Technologies Privacy Notice.